185 related articles for article (PubMed ID: 1931612)
1. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
Kawa S; Oguchi H; Kobayashi T; Tokoo M; Furuta S; Kanai M; Homma T
Br J Cancer; 1991 Nov; 64(5):899-902. PubMed ID: 1931612
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Hsue GL; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Ichikawa T; Kanai M
Scand J Gastroenterol; 1992 Aug; 27(8):635-43. PubMed ID: 1359630
[TBL] [Abstract][Full Text] [Related]
3. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose.
Kawa S; Tokoo M; Oguchi H; Furuta S; Homma T; Hasegawa Y; Ogata H; Sakata K
Pancreas; 1994 Nov; 9(6):692-7. PubMed ID: 7531332
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
5. Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Kobayashi T; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Sep; 26(9):981-92. PubMed ID: 1682994
[TBL] [Abstract][Full Text] [Related]
6. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
Hirano K; Kawa S; Oguchi H; Kobayashi T; Yonekura H; Ogata H; Homma T
J Natl Cancer Inst; 1987 Dec; 79(6):1261-8. PubMed ID: 2447318
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
8. Expression of blood group-related antigens in normal and malignant pancreatic tissue correlated with genotype of the patient defined by saliva glycoprotein.
Ichihara T; Sakamoto J; Nakao A; Furukawa K; Watanabe T; Suzuki N; Horisawa M; Nagura H; Lloyd KO; Takagi H
Cancer; 1993 Jan; 71(1):71-81. PubMed ID: 8416729
[TBL] [Abstract][Full Text] [Related]
9. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Usefulness in Patients with Normal CA19-9.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5801-5802. PubMed ID: 37355518
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
11. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA50.
Kawa S; Kato M; Oguchi H; Kobayashi T; Hsue GL; Koiwai T; Aoki Y; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Dec; 26(12):1307-18. PubMed ID: 1662409
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5792-5800. PubMed ID: 37248377
[TBL] [Abstract][Full Text] [Related]
13. The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype.
Shimojo N; Naka K; Nakajima C; Ishizaki T; Okuda K; Murai J; Yamamoto M
Clin Chim Acta; 1990 Oct; 190(3):283-9. PubMed ID: 1979260
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
15. Investigation of unexpected serum CA19-9 elevation in Lewis-negative cancer patients.
Hamada E; Taniguchi T; Baba S; Maekawa M
Ann Clin Biochem; 2012 May; 49(Pt 3):266-72. PubMed ID: 22492877
[TBL] [Abstract][Full Text] [Related]
16. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type.
Pour PM; Tempero MM; Takasaki H; Uchida E; Takiyama Y; Burnett DA; Steplewski Z
Cancer Res; 1988 Oct; 48(19):5422-6. PubMed ID: 3166398
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
18. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
Narimatsu H; Iwasaki H; Nakayama F; Ikehara Y; Kudo T; Nishihara S; Sugano K; Okura H; Fujita S; Hirohashi S
Cancer Res; 1998 Feb; 58(3):512-8. PubMed ID: 9458099
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease.
von Rosen A; Linder S; Harmenberg U; Pegert S
Pancreas; 1993 Mar; 8(2):160-5. PubMed ID: 8460090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]